We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+15.27%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$17.3B
AUM Growth
+$1.38B
Cap. Flow
-$440M
Cap. Flow %
-2.54%
Top 10 Hldgs %
32.07%
Holding
728
New
61
Increased
216
Reduced
343
Closed
55

Top Buys

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$85M
2
ABT icon
Abbott
ABT
+$53.8M
3
EXC icon
Exelon
EXC
+$46.6M
4
BSX icon
Boston Scientific
BSX
+$42.6M
5
ABBV icon
AbbVie
ABBV
+$32.4M

Top Sells

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$80.5M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$54.5M
3
CRWD icon
CrowdStrike
CRWD
+$45.7M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$40.6M
5
MRK icon
Merck
MRK
+$39.3M

Sector Composition

Rank Sector Weight
1 Technology 36.26%
2 Healthcare 22.78%
3 Financials 10.33%
4 Consumer Discretionary 7.75%
5 Industrials 7.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NEE icon
101
NextEra Energy
NEE
$187B
$36.2M 0.21%
521,211
-331,253
-39% -$23M
RL icon
102
Ralph Lauren
RL
$22.2B
$35.6M 0.21%
94,987
+15,513
+20% +$3.84M
MTD icon
103
Mettler-Toledo International
MTD
$26.8B
$35.5M 0.2%
30,191
+243
+0.8% +$272K
OTIS icon
104
Otis Worldwide
OTIS
$27.4B
$34.9M 0.2%
352,136
-97,992
-22% -$9.46M
EQIX icon
105
Equinix
EQIX
$107B
$34.2M 0.2%
42,969
+13,422
+45% +$11.4M
ORCL icon
106
Oracle
ORCL
$331B
$34M 0.2%
155,363
+36,975
+31% +$5.97M
ASND icon
107
Ascendis Pharma A/S
ASND
$16.7B
$33.7M 0.19%
195,115
-47,646
-20% -$7.76M
XOM icon
108
ExxonMobil
XOM
$651B
$33.5M 0.19%
310,425
-21,672
-7% -$2.32M
ALL icon
109
Allstate
ALL
$66.9B
$33.1M 0.19%
164,313
-44,196
-21% -$8.82M
CMCSA icon
110
Comcast
CMCSA
$79.1B
$32.8M 0.19%
919,892
+58,564
+7% +$2.03M
FTNT icon
111
Fortinet
FTNT
$112B
$32.7M 0.19%
309,556
+69,868
+29% +$7.05M
PNC icon
112
PNC Financial Services
PNC
$100B
$30.9M 0.18%
165,490
-78,490
-32% -$13.3M
BMRN icon
113
BioMarin Pharmaceuticals
BMRN
$11.5B
$30.2M 0.17%
549,655
-58,207
-10% -$3.43M
CL icon
114
Colgate-Palmolive
CL
$72.6B
$30.2M 0.17%
332,009
-8,543
-3% -$780K
OLED icon
115
Universal Display
OLED
$3.71B
$30.2M 0.17%
195,306
-711
-0.4% -$99.6K
CAH icon
116
Cardinal Health
CAH
$53.4B
$29.7M 0.17%
177,008
+151,988
+607% +$22.6M
WCN
117
Waste Connections
WCN
$42.8B
$29.6M 0.17%
158,674
-47,011
-23% -$9.06M
TMUS icon
118
T-Mobile US
TMUS
$193B
$28.9M 0.17%
121,166
-9,100
-7% -$2.22M
IONS icon
119
Ionis Pharmaceuticals
IONS
$9.35B
$28.6M 0.17%
724,740
-268,964
-27% -$8.8M
LAUR icon
120
Laureate Education
LAUR
$5.18B
$28.4M 0.16%
1,214,700
+1,015,711
+510% +$21.8M
MTZ icon
121
MasTec
MTZ
$26.7B
$28M 0.16%
164,497
+122,568
+292% +$17.7M
NKE icon
122
Nike
NKE
$61.9B
$27.4M 0.16%
385,298
+296,194
+332% +$17.8M
DDOG icon
123
Datadog
DDOG
$87.9B
$27.3M 0.16%
203,573
-105
-0.1% -$11.6K
CHE icon
124
Chemed
CHE
$6.78B
$27.1M 0.16%
55,609
+10,431
+23% +$5.94M
IQV icon
125
IQVIA
IQV
$34.7B
$26.7M 0.15%
169,180
+26,144
+18% +$3.94M

Similar funds

Candriam SCA's Q2 2025 Portfolio in Review

As of Q2 2025, Candriam SCA held 728 positions worth $17.3B, up 8.6% from $16B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Candriam SCA's Q2 2025 filing shows 61 new, 216 increased, 343 reduced and 55 closed positions. Its largest new stake was Tapestry: 260,834 shares worth $22.9M. The largest sale was Tesla, an estimated $80.5M.

By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 32% a quarter earlier, followed by Healthcare and Financials.

  • Candriam SCA's largest Q2 2025 buy was Tapestry: 260,834 shares worth $22.9M.
  • Candriam SCA added most to Broadcom in Q2 2025, an estimated $85M increase.
  • Candriam SCA's biggest Q2 2025 reduction was Tesla, cutting an estimated $80.5M.
  • Candriam SCA fully exited Banco Macro in Q2 2025, selling an estimated $17.6M.
  • Candriam SCA's ten largest holdings make up 32% of its $17.3B portfolio in Q2 2025.
  • Candriam SCA opened 61 new positions and closed 55 in Q2 2025.
  • Candriam SCA's portfolio value rose 8.6% quarter-over-quarter to $17.3B.

Based on Candriam SCA's 13F filing for Q2 2025, filed 8 Aug 2025.